A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients

NCT ID: NCT05332470

Last Updated: 2022-04-18

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-05-01
• Study Completion Date: 2025-05-31

Brief Summary

Actual update to the US Department of Health and Human Services treatment guidelines for HIV-1 infection and European AIDS Clinical Society guidelines indicate Dovato(Dolutegravir/lamivudine) as an initial treatment in HIV-naÏve patients. However there is no real- life data. The investigators' results in real life have encouraged us to conduct a multicenter cohort study in patients who have already started their first antiretroviral therapy with DTG (dolutegravir) + 3TC(lamivudine ), to verify efficacy and tolerance in real life. The investigators' hypothesis is that the data will be similar to those reported in clinical trials.

Detailed Description

Since 1996, HAART(Highly Active Antiretroviral Therapy) based on 3DR(3-drug regimens ) in PLHIV(people living with HIV) has decreased mortality and today, PLHIV have a life expectancy close to that of the general population. In the last decade new drugs have improved tolerance and posology of these treatment. However PLHIV needs to continue the treatment and will likely remain on antiviral therapy for many years. In the recent period, active research is being sought with the aim of improving the dosage and reducing the amount of drugs necessary to maintain efficacy, to avoid the possible cumulative effects of long-term ART (antiretroviral therapy). 2DRs(Two-drug regimens) have been investigated as a means for reducing the number of ARVs(antiretroviral agents) taken by individuals who need lifelong ART. Dovato has been evaluated in two phase III studies (GEMINI-1 and GEMINI-2) in treatment-naive adults achieving non inferiority according to the US FDA (Food and Drug Administration) Snapshot algorithm. These data led to the approval of the fixed-dose combination of dolutegravir/lamivudine as a once-daily, single-tablet 2DR by the FDA and the European Medicines Agency. Actual update to the US Department of Health and Human Services treatment guidelines for HIV-1 infection and European AIDS Clinical Society guidelines indicate Dovato as an initial treatment in HIV-naÏve patients. However there is no real- life data. The investigators' aim is to provide information related to effectiveness and tolerability/safety in naïve patients when used in routine clinical practice. It has been already published results from the phase III study in pretreatment adult patients.

The investigators' results in real life have encouraged us to conduct a multicenter cohort study in patients who have already started their first antiretroviral therapy with DTG (dolutegravir) + 3TC(lamivudine ), to verify efficacy and tolerance in real life. The investigators' hypothesis is that the data will be similar to those reported in clinical trials.

Conditions

HIV-1-infection

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Interventions

Lamivudine and Dotiravir Sodium Tablets

3TC (300 mg p.o. q 24 h) plus DTG (50 mg p.o. q 24 h)

Intervention Type: DRUG

Other Intervention Names

Dovato

Eligibility Criteria

Inclusion Criteria

1. Understand and sign the written informed consent ;

2. Over 18 years old;

3. Western Blot test confirmed HIV positive, and did not take any antiretroviral therapy;

4. HIV viral load ≥1000 copies/ml ;

5. Uncomplicated hepatitis B virus infection: HBsAg (-) ;

6. Estimated glomerular filtration rate (GFR) > 30ml/min (calculated by CKD - EPI);

7. No serious liver function damage (Child C ) ;

8. Be able to carry out antiviral treatment and regular follow-up according to the plan.

Exclusion Criteria

1. Previously used ART or used PreP or PEP ;

2. Have a history of mental or nervous system diseases or suicidal tendencies;

3. Severe cardiovascular and respiratory system diseases, liver and kidney function damage, coagulation dysfunction, thrombocytopenia, circulatory system diseases, etc.;

4. There are indications of glucocorticoid application during application or follow-up period;

5. Radiotherapy, chemotherapy, cell therapy or therapeutic vaccine, immunomodulatory therapy, etc. are required within 28 days before the start of the study or during the study period;

6. Participate in other drug trials;

7. Those who are pregnant, breastfeeding or planning to become pregnant within one year;

8. Poor compliance, unable to follow up on schedule.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking Union Medical College Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

WEI Lyu

Role: PRINCIPAL_INVESTIGATOR

Department of Infectious Diseases, PekingUMCH

Central Contacts

QING ZHANG

Role: CONTACT

zhangqingpumch@163.com

15001278131 ext. +86

Other Identifiers

PekingUMCH record ZS-3419D

Identifier Type: -

Identifier Source: org_study_id